Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Identification of a shared, common haplotype cosegregating with an SGCB c.544A>C mutation in Indian patients affected with sarcoglycanopathy

Shamita Sanga, Sudipta Chakraborty, Mainak Bardhan, Atchayaram Nalini, View ORCID ProfileMoulinath Acharya
doi: https://doi.org/10.1101/2021.12.03.21266857
Shamita Sanga
1National Institute of Biomedical Genomics, Kalyani, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudipta Chakraborty
1National Institute of Biomedical Genomics, Kalyani, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mainak Bardhan
2Department of Neurology, National Institute of Mental Health and Neuroscience, Bengaluru, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atchayaram Nalini
2Department of Neurology, National Institute of Mental Health and Neuroscience, Bengaluru, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moulinath Acharya
1National Institute of Biomedical Genomics, Kalyani, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Moulinath Acharya
  • For correspondence: ma1@nibmg.ac.in
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Sarcoglycanopathies (SG) is the most frequent form of autosomal recessive limb-girdle muscular dystrophies (LGMD) leading to progressive muscle wasting and weakness, predominantly characterized by limb-girdle weakness. LGMDR4 is caused by mutations in SGCB encoding for the beta-sarcoglycan proteins. In this study, we describe a shared, common haplotype cosegregating in 14 SG cases from 13 unrelated families with the likely pathogenic homozygous mutation c.544A>C (p.Thr182Pro) in SGCB.

Methods The genotypes of five selected markers (rs10009426, rs6824707, rs2271046, rs35414474 and rs17611952) surrounding the c.544A>C (p.Thr182Pro) were extracted from the variant call format (VCF) generated from whole-exome sequencing (WES) of 14 cases and 14 related family members as controls. The linkage data file was constructed and linkage disequilibrium (LD) plots were generated using HaploView to visualize patterns of LD. Further, haplotype reconstructions based on the 6 markers were conducted using PLINK1.9. using the expectation-maximization (EM) algorithm, an iterative method to find maximum likelihood. Subsequently, the R programming language was used to determine and compare plots of the haplotype frequencies and percentages for both groups to infer the risk haplotypes.

Results Four strong LD blocks were identified in control group: rs10009426 to rs6824707 (0.27□kb), rs6824707 to rs2271046 (41.6 kb), rs10009426 to rs2271046 (41.8 kb) and rs35414474 to rs17611952 (0.17 kb) which were absent in the case group. Similarly, a total of nine haplotypes were estimated in cases and controls of which haplotype H1= G, A, T, G, G, T showed significant statistical difference in the frequency between cases and controls. H1 is also observed to cosegregate with c.544A>C (p.Thr182Pro) in the pedigrees of all the cases.

Conclusion The identification of c.544A>C (p.Thr182Pro) mutation in 14 cases from India indicates a probable event of founder effect. Further, the H1 haplotype, cosegregating with this mutation, convincingly sheds light on the recent developments in population genetics allowing insights into demographic and population history. This haplotype can also be used as a genetic marker to screen individuals with genetic susceptibility as carriers and provide genetically informed risk stratification and management in the prevention of SG.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by NIBMG intramural support

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the institutional ethics committee (NIMHANS/IEC/2020-21). Written informed consent was obtained from all participants in the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interest statement The authors declare no conflict of interest.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Identification of a shared, common haplotype cosegregating with an SGCB c.544A>C mutation in Indian patients affected with sarcoglycanopathy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Identification of a shared, common haplotype cosegregating with an SGCB c.544A>C mutation in Indian patients affected with sarcoglycanopathy
Shamita Sanga, Sudipta Chakraborty, Mainak Bardhan, Atchayaram Nalini, Moulinath Acharya
medRxiv 2021.12.03.21266857; doi: https://doi.org/10.1101/2021.12.03.21266857
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Identification of a shared, common haplotype cosegregating with an SGCB c.544A>C mutation in Indian patients affected with sarcoglycanopathy
Shamita Sanga, Sudipta Chakraborty, Mainak Bardhan, Atchayaram Nalini, Moulinath Acharya
medRxiv 2021.12.03.21266857; doi: https://doi.org/10.1101/2021.12.03.21266857

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1245)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (534)
  • Epidemiology (10032)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2467)
  • Geriatric Medicine (238)
  • Health Economics (480)
  • Health Informatics (1647)
  • Health Policy (754)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11872)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2290)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1249)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (734)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4844)
  • Radiology and Imaging (843)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (652)
  • Rheumatology (286)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (269)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)